Filings monitor · SYK

What STRYKER CORP's SEC filings said

10-Q for 2026Q3, filed 30 Oct 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. CEO exit70 · rule score among filings · 8-K Item 5.02 · 6 Oct 2026
   Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the…
2. Guidance / Outlook69 · importance in its document · 8-K exhibit · 29 Oct 2026
   On October 29, 2026, Stryker updated its full-year 2026 outlook to organic net sales growth of 6.5%–7.0% and adjusted diluted EPS of $14.80–$14.90. The sales outlook includes a modestly positive pricing impact. Foreign exchange is…
3. Income Tax Rate Changes60 · importance in its document · 10-Q · 2026Q3
   The effective tax rate was 24.5% in the third quarter of 2026, compared with 16.5% in the third quarter of 2025.,For the first nine months, the effective tax rate increased to 18.7% from 14.7%.,The third-quarter increase was attributed to the nondeductible $293 million goodwill impairment related to Peripheral Vascular.,The nine-month rate increase reflected the nondeductible goodwill impairment and the prior-year tax benefit associated with the sale of the Spinal Implants business.
4. Gross Margin Drivers54 · importance in its document · 10-Q · 2026Q3
   Third-quarter gross profit rose to $4,248 million from $3,852 million, and gross margin increased to 65.2% from 63.6%.,Quarterly margin improvement reflected 60 basis points from volume and mix and 100 basis points from lower amortization of inventory stepped up to fair value; manufacturing and supply-chain costs reduced margin by 20 basis points.,Nine-month gross profit was $12,556 million versus $11,437 million, and gross margin increased to 65.6% from 63.7%.,Nine-month margin benefited from a 90-basis-point reversal of 2025 tariffs and 90 basis points from lower inventory step-up amortization, partly offset by an 80-basis-point increase in manufacturing and supply-chain costs, primarily tied to idle production time from the first-quarter 2026 cybersecurity incident.
5. Operating Expense Trends54 · importance in its document · 10-Q · 2026Q3
   Third-quarter selling, general and administrative expense increased $268 million, or 13.1%, to $2,313 million, and rose to 35.5% of sales from 33.8%, primarily because of higher structural optimization and other special charges.,Nine-month SG&A increased $399 million, or 6.2%, to $6,823 million, while its sales ratio was nearly flat at 35.7% versus 35.8%.,Nine-month research, development and engineering expense increased $58 million, or 4.7%, to $1,280 million; it was 6.7% of sales compared with 6.8% a year earlier.,Higher nine-month structural optimization and other special charges were offset by lower acquisition and integration-related costs.

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 30 Oct 2026

Full report · Filing on EDGAR

• Income Tax Rate ChangesImportance 60
  The effective tax rate was 24.5% in the third quarter of 2026, compared with 16.5% in the third quarter of 2025.,For the first nine months, the effective tax rate increased to 18.7% from 14.7%.,The third-quarter increase was attributed to the nondeductible $293 million goodwill impairment related to Peripheral Vascular.,The nine-month rate increase reflected the nondeductible goodwill impairment and the prior-year tax benefit associated with the sale of the Spinal Implants business.
• Gross Margin DriversImportance 54
  Third-quarter gross profit rose to $4,248 million from $3,852 million, and gross margin increased to 65.2% from 63.6%.,Quarterly margin improvement reflected 60 basis points from volume and mix and 100 basis points from lower amortization of inventory stepped up to fair value; manufacturing and supply-chain costs reduced margin by 20 basis points.,Nine-month gross profit was $12,556 million versus $11,437 million, and gross margin increased to 65.6% from 63.7%.,Nine-month margin benefited from a 90-basis-point reversal of 2025 tariffs and 90 basis points from lower inventory step-up amortization, partly offset by an 80-basis-point increase in manufacturing and supply-chain costs, primarily tied to idle production time from the first-quarter 2026 cybersecurity incident.
• Operating Expense TrendsImportance 54
  Third-quarter selling, general and administrative expense increased $268 million, or 13.1%, to $2,313 million, and rose to 35.5% of sales from 33.8%, primarily because of higher structural optimization and other special charges.,Nine-month SG&A increased $399 million, or 6.2%, to $6,823 million, while its sales ratio was nearly flat at 35.7% versus 35.8%.,Nine-month research, development and engineering expense increased $58 million, or 4.7%, to $1,280 million; it was 6.7% of sales compared with 6.8% a year earlier.,Higher nine-month structural optimization and other special charges were offset by lower acquisition and integration-related costs.
• Operating Income and MarginsImportance 54
  Third-quarter operating income was $1,034 million, down from $1,135 million, and operating margin fell to 15.9% from 18.7%.,Nine-month operating income increased to $3,629 million from $3,085 million, with operating margin rising to 19.0% from 17.2%.,Third-quarter MedSurg and Neurotechnology operating margin rose to 28.7% from 26.1%, primarily due to lower SG&A, lower manufacturing and supply-chain costs, and higher unit volumes.,Third-quarter Orthopaedics operating margin declined to 31.2% from 32.4%, as higher SG&A and manufacturing and supply-chain costs partly offset higher unit volumes.
• Supply Chain ConstraintsImportance 52
  Stryker reported that Peripheral Vascular operating results were affected by near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery. The company’s…
• Other Income (Expense), NetImportance 51
  Other income increased to $106 million in the third quarter of 2026 from $51 million a year earlier, a 107.8% increase.,Nine-month other income rose to $214 million from $177 million, a 20.9% increase.,The increases in both periods were primarily due to income from intellectual-property licensing in 2026.
• Revenue Performance and MixImportance 49
  Third-quarter 2026 net sales increased 7.7% to $6,520 million, with constant-currency growth of 7.6% driven by unit volume and 0.1% by higher prices.,Nine-month 2026 net sales increased 6.6% to $19,129 million; constant-currency growth was 5.9%, and organic constant-currency growth was 6.2% after excluding a 0.5% acquisition and divestiture impact.,MedSurg and Neurotechnology sales grew 9.2% in the quarter and 8.0% for nine months, while Orthopaedics sales grew 5.7% and 4.9%, respectively.,For the nine months, U.S. sales increased 6.0% to $14,385 million and international sales increased 8.3% to $4,744 million.
• Market Demand TrendsImportance 49
  Consolidated net sales increased 7.7% in the third quarter and 6.6% for the first nine months of 2026. Growth was primarily volume-driven, with higher product shipments across all MedSurg and Neurotechnology businesses…
• Balance Sheet and LiquidityImportance 46
  Cash, cash equivalents, short-term investments and marketable securities totaled $3,271 million at September 30, 2026, down from $4,100 million at December 31, 2025.,Current assets exceeded current liabilities by $7,683 million at September 30, 2026, compared with $6,961 million at December 31, 2025.,Cash, cash equivalents, short-term investments and marketable securities held outside the United States represented approximately 44% of the total at September 30, 2026, versus 20% at December 31, 2025.,Nine-month operating cash flow increased to $3,303 million from $2,901 million, primarily because higher net earnings were partly offset by working-capital changes.
• Geographic Market CommentaryImportance 43
  United States sales increased 8.3% in the third quarter and 6.0% for the first nine months of 2026. International sales increased 5.7% in the quarter and 8.3% year to date as reported; constant-currency growth was 6.0%…
• Acquisition / Partnership / DivestitureImportance 34
  Stryker completed the acquisition of AVS during the first nine months of 2026, and the period’s investing cash flows included the net cash consideration paid for the acquisition.,Nine-month investing activities used $1,011 million in cash, compared with $4,561 million in the prior-year period.,The filing also identifies the prior-year acquisition of Inari and the sale of the Spinal Implants business; the Spinal Implants sale generated a tax benefit that affected the nine-month effective tax-rate comparison.
• Guidance / OutlookImportance 33
  Management expects segment mix to have an unfavorable impact on gross margin for the foreseeable future. This outlook reflects anticipated faster sales growth in the lower-gross-margin MedSurg and Neurotechnology…

8-K filings last 12 months

• Other officer change9 Nov 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On November 3, 2026, the Board of Directors of Stryker Corporation (the “Company”) increased the number of authorized directors from 11 to 12 and elected James E. Davis to fill the resulting vacancy.”
• Results, no stated guidance change29 Oct 2026 · 8-K Item 2.02 · Routine · rule score 10
  Read from the attached exhibit: Guidance / Outlook · Capital Return Program · Operating Expense Trends
• CEO exit6 Oct 2026 · 8-K Item 5.02 · Flagged · rule score 70
  “Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the…”
  Read from the attached exhibit: Leadership Transition
• Results (release not read)30 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Operating Income and Margins · Guidance / Outlook · Restructuring Charges
• Press release attached to an 8-K26 Jun 2026 · 8-K
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Income Tax Rate Changes · Capital Allocation
• Executive pay change20 May 2026 · 8-K Item 5.02 · Routine · rule score 5
  “Stryker Corporation (the “Company”) announced on May 20, 2026 that William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026 and that Emily Baculik,…”
• Results (release not read)30 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)29 Jan 2026 · 8-K Item 2.02 · Routine · rule score 20
• Other officer change4 Dec 2025 · 8-K Item 5.02 · Routine · rule score 15
  “Stryker Corporation (the “Company”) announced on December 4, 2025 that Spencer Stiles, who currently serves as Group President, Orthopaedics, has been appointed President and Chief Operating Officer of the Company effective January 1, 2026.”

Earlier reports

• 10-Q · 2026Q2filed 31 Jul 2026
  Restructuring Charges · Cash Flow and Capital Allocation · Operating Income and Margins

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.